VIDEO: Patients with DED can benefit from light heat therapy
Click Here to Manage Email Alerts
CARLSBAD, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Yuna Rapoport, MD, MPH, of Manhattan Eye, discusses light heat therapy for dry eye disease and lotilaner for Demodex blepharitis.
In her first presentation, Rapoport discussed a post-hoc analysis of the Saturn-1 and Saturn-2 clinical trials. The analysis compared patients who received a vehicle control with those who received Xdemvy (lotilaner ophthalmic solution 0.25%, Tarsus Pharmaceuticals) and assessed whether they experienced improvement.
“Demodex blepharitis is a continuous disease,” she said. “It is not self-remitting, and patients who have this really should be treated, because otherwise their symptoms will get worse.”
The second presentation was an analysis of patients with dry eye who underwent light heat therapy versus Restasis (cyclosporine ophthalmic emulsion 0.05%, AbbVie).
“Even in patients who have stopped their medicated cyclosporine, which is one of the most common medications for dry eye, they really benefit from even one light heat therapy,” Rapoport said.
References:
- Rapoport Y. Tear break-up, meibomian gland, and dry eye symptom improvement for cyclosporine-treated patients after localized heat therapy treatment. Presented at: Women in Ophthalmology Summer Symposium; Aug. 22-25, 2024; Carlsbad, California.
- Rapoport Y. Worsening or no improvement in demodex blepharitis in patients receiving vehicle control vs. lotilaner ophthalmic solution, 0.25%. Presented at: Women in Ophthalmology Summer Symposium; Aug. 22-25, 2024; Carlsbad, California.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts